60
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Mycobacterium tuberculosis resistance to anti-tuberculosis drugs is a major threat to global public health. Whole genome sequencing (WGS) is rapidly gaining traction as a diagnostic tool for clinical tuberculosis settings. To support this informatically, previous work led to the development of the widely used TBProfiler webtool, which predicts resistance to 14 drugs from WGS data. However, for accurate and rapid high throughput of samples in clinical or epidemiological settings, there is a need for a stand-alone tool and the ability to analyse data across multiple WGS platforms, including Oxford Nanopore MinION.

          Results

          We present a new command line version of the TBProfiler webserver, which includes hetero-resistance calling and will facilitate the batch processing of samples. The TBProfiler database has been expanded to incorporate 178 new markers across 16 anti-tuberculosis drugs. The predictive performance of the mutation library has been assessed using > 17,000 clinical isolates with WGS and laboratory-based drug susceptibility testing (DST) data. An integrated MinION analysis pipeline was assessed by performing WGS on 34 replicates across 3 multi-drug resistant isolates with known resistance mutations. TBProfiler accuracy varied by individual drug. Assuming DST as the gold standard, sensitivities for detecting multi-drug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) were 94% (95%CI 93–95%) and 83% (95%CI 79–87%) with specificities of 98% (95%CI 98–99%) and 96% (95%CI 95–97%) respectively. Using MinION data, only one resistance mutation was missed by TBProfiler, involving an insertion in the tlyA gene coding for capreomycin resistance. When compared to alternative platforms (e.g. Mykrobe predictor TB, the CRyPTIC library), TBProfiler demonstrated superior predictive performance across first- and second-line drugs.

          Conclusions

          The new version of TBProfiler can rapidly and accurately predict anti-TB drug resistance profiles across large numbers of samples with WGS data. The computing architecture allows for the ability to modify the core bioinformatic pipelines and outputs, including the analysis of WGS data sourced from portable technologies. TBProfiler has the potential to be integrated into the point of care and WGS diagnostic environments, including in resource-poor settings.

          Electronic supplementary material

          The online version of this article (10.1186/s13073-019-0650-x) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references11

          • Record: found
          • Abstract: not found
          • Article: not found

          Bioconda: sustainable and comprehensive software distribution for the life sciences

            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Rapid antibiotic-resistance predictions from genome sequence data for Staphylococcus aureus and Mycobacterium tuberculosis

            The rise of antibiotic-resistant bacteria has led to an urgent need for rapid detection of drug resistance in clinical samples, and improvements in global surveillance. Here we show how de Bruijn graph representation of bacterial diversity can be used to identify species and resistance profiles of clinical isolates. We implement this method for Staphylococcus aureus and Mycobacterium tuberculosis in a software package (‘Mykrobe predictor') that takes raw sequence data as input, and generates a clinician-friendly report within 3 minutes on a laptop. For S. aureus, the error rates of our method are comparable to gold-standard phenotypic methods, with sensitivity/specificity of 99.1%/99.6% across 12 antibiotics (using an independent validation set, n=470). For M. tuberculosis, our method predicts resistance with sensitivity/specificity of 82.6%/98.5% (independent validation set, n=1,609); sensitivity is lower here, probably because of limited understanding of the underlying genetic mechanisms. We give evidence that minor alleles improve detection of extremely drug-resistant strains, and demonstrate feasibility of the use of emerging single-molecule nanopore sequencing techniques for these purposes.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              DNA Sequencing Predicts 1st-Line Tuberculosis Drug Susceptibility Profiles

              Background The World Health Organization recommends universal drug susceptibility testing for Mycobacterium tuberculosis complex to guide treatment decisions and improve outcomes. We assessed whether DNA sequencing can accurately predict antibiotic susceptibility profiles for first-line anti-tuberculosis drugs. Methods Whole-genome sequences and associated phenotypes to isoniazid, rifampicin, ethambutol and pyrazinamide were obtained for isolates from 16 countries across six continents. For each isolate, mutations associated with drug-resistance and drug-susceptibility were identified across nine genes, and individual phenotypes were predicted unless mutations of unknown association were also present. To identify how whole-genome sequencing might direct first-line drug therapy, complete susceptibility profiles were predicted. These were predicted to be pan-susceptible if predicted susceptible to isoniazid and to other drugs, or contained mutations of unknown association in genes affecting these other drugs. We simulated how negative predictive value changed with drug-resistance prevalence. Results 10,209 isolates were analysed. The greatest proportion of phenotypes were predicted for rifampicin (9,660/10,130; (95.4%)) and the lowest for ethambutol (8,794/9,794; (89.8%)). Isoniazid, rifampicin, ethambutol and pyrazinamide resistance was correctly predicted with 97.1%, 97.5% 94.6% and 91.3% sensitivity, and susceptibility with 99.0%, 98.8%, 93.6% and 96.8% specificity, respectively. 5,250 (89.5%) drug profiles were correctly predicted for 5,865/7,516 (78.0%) isolates with complete phenotypic profiles. Among these, 3,952/4,037 (97.9%) predictions of pan-susceptibility were correct. The negative predictive value for 97.5% of simulated drug profiles exceeded 95% where the prevalence of drug-resistance was below 47.0%. Conclusions Phenotypic testing for first-line drugs can be phased down in favour of DNA sequencing to guide anti- tuberculosis drug therapy.
                Bookmark

                Author and article information

                Contributors
                jody.phelan@lshtm.ac.uk
                denise.osullivan@lgcgroup.com
                diana@ihmt.unl.pt
                jorge@ihmt.unl.pt
                yaa.oppong@lshtm.ac.uk
                susana.campino@lshtm.ac.uk
                justin.ogrady@uea.ac.uk
                ruth.mcnerney@gmail.com
                martin.hibberd@lshtm.ac.uk
                MViveiros@ihmt.unl.pt
                Jim.Huggett@lgcgroup.com
                taane.clark@lshtm.ac.uk
                Journal
                Genome Med
                Genome Med
                Genome Medicine
                BioMed Central (London )
                1756-994X
                24 June 2019
                24 June 2019
                2019
                : 11
                : 41
                Affiliations
                [1 ]ISNI 0000 0004 0425 469X, GRID grid.8991.9, Faculty of Infectious and Tropical Diseases, , London School of Hygiene & Tropical Medicine, ; London, WC1E 7HT UK
                [2 ]ISNI 0000 0004 0556 5940, GRID grid.410519.8, Molecular Biology, , LGC Ltd, ; Queens Road, Teddington, Middlesex, TW11 0LY UK
                [3 ]ISNI 0000000121511713, GRID grid.10772.33, Global Health and Tropical Medicine, GHTM, Instituto de Higiene e Medicina Tropical, IHMT, , Universidade NOVA de Lisboa, UNL, ; Lisbon, Portugal
                [4 ]ISNI 0000 0001 1092 7967, GRID grid.8273.e, Norwich Medical School, , University of East Anglia, ; Norwich Research Park, Norwich, NR4 7TJ UK
                [5 ]ISNI 0000 0004 1937 1151, GRID grid.7836.a, Department of Medicine, , University of Cape Town, ; Observatory, Cape Town, 7925 South Africa
                [6 ]ISNI 0000 0004 0407 4824, GRID grid.5475.3, School of Biosciences & Medicine, Faculty of Health & Medical Science, , University of Surrey, ; Guildford, GU2 7XH UK
                [7 ]ISNI 0000 0004 0425 469X, GRID grid.8991.9, Faculty of Epidemiology and Population Health, , London School of Hygiene & Tropical Medicine, ; London, WC1E 7HT UK
                Author information
                http://orcid.org/0000-0001-8985-9265
                Article
                650
                10.1186/s13073-019-0650-x
                6591855
                31234910
                bfadd50a-d98b-49a7-8d27-b372fec3e0b9
                © The Author(s). 2019

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 8 April 2019
                : 30 May 2019
                Funding
                Funded by: UK National Measurement System and the European Metrology Programme for Innovation and Research
                Award ID: HLT07
                Funded by: FundRef http://dx.doi.org/10.13039/100010897, Newton Fund;
                Award ID: British Council. 261868591
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100000265, Medical Research Council;
                Award ID: MR/M01360X/1
                Award ID: MR/N010469/1
                Award ID: MR/R025576/1
                Award Recipient :
                Funded by: Medical Research Council (GB)
                Award ID: MR/R020973/1
                Award ID: MR/R020973/1
                Award ID: MR/M01360X/1
                Award ID: MR/R025576/1
                Award Recipient :
                Funded by: Biotechnology and Biological Sciences Research Council (GB)
                Award ID: BB/R013063/1
                Award Recipient :
                Funded by: Fundação para a Ciência e a Tecnologia (PT)
                Award ID: SFRH/BPD/100688/2014
                Award ID: GHTMUID/Multi/04413/2013
                Award Recipient :
                Funded by: UK Antimicrobial Resistance Cross Council Initiative
                Award ID: MR/N013956/1
                Award Recipient :
                Funded by: Rosetrees Trust (GB)
                Award ID: A749
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100001871, Fundação para a Ciência e a Tecnologia;
                Award ID: GHTMUID/Multi/04413/2013
                Award ID: GHTMUID/Multi/04413/2013
                Award Recipient :
                Categories
                Software
                Custom metadata
                © The Author(s) 2019

                Molecular medicine
                drug resistance,tuberculosis,diagnostics,drug-susceptibility testing,mdr-tb,xdr-tb,wgs
                Molecular medicine
                drug resistance, tuberculosis, diagnostics, drug-susceptibility testing, mdr-tb, xdr-tb, wgs

                Comments

                Comment on this article